Concepedia

Author

N. Zanaletti

University of Campania "Luigi Vanvitelli"ORCID

Also Known As

N. Zanaletti, Nicoletta Zanaletti, Zanaletti, Nicoletta

57

Publications

619

Citations

12

H-Index

27

Concepts

All Affiliations

University of Campania "Luigi Vanvitelli"Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Istituti di Ricovero e Cura a Carattere ScientificoCasa Sollievo della SofferenzaCandiolo Cancer Institute
NZ

About

N. Zanaletti is an author at University of Campania "Luigi Vanvitelli" specializing in colorectal cancer, radiation oncology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

116

2

Pathology

2

2

75

3

Health Sciences

1

1

65

4

Gastroenterology

1

1

10

5

Immunology

1

1

10

N. Zanaletti

×

14

Publications

519

Citations

11

H-Index

YearCitations

Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With <i>RAS</i> Wild-type Metastatic Colorectal Cancer

Erika Martinelli, Giulia Martini, Vincenzo Famiglietti,

JAMA Oncology

2021

174

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer

Joris van de Haar, Xuhui Ma, Salo Ooft,

Nature Medicine

2023

74

Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience

Pietro Paolo Vitiello, Vincenzo De Falco, Emilio Francesco Giunta,

Cancers

2019

65

Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients

Emilio Francesco Giunta, Giusi Barra, Vincenzo De Falco,

Scientific Reports

2020

34

491P Neoadjuvant nivolumab in early stage colorectal cancer

Antonio Avallone, Alfonso De Stefano, Ugo Pace,

Annals of Oncology

2020

30

Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania ‘Luigi Vanvitelli’

Vincenzo De Falco, L. Poliero, Pietro Paolo Vitiello,

ESMO Open

2020

22

Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data

Pasquale Vitale, N. Zanaletti, Vincenzo Famiglietti,

Clinical Colorectal Cancer

2021

22

Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study

Alessandro Parisi, Alessio Cortellini, Katia Cannita,

Cancers

2020

21

Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis

Maria Antonietta Isgrò, Maria Grazia Vitale, Egidio Celentano,

Journal of Translational Medicine

2021

19

Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme

Vincenzo Sforza, Erika Martinelli, Claudia Cardone,

ESMO Open

2017

15

Page 1